OrbusNeich Medical Group Holdings Ltd
HKEX:6929
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.86
8
|
Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
OrbusNeich Medical Group Holdings Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | HK |
Market Cap | 3.4B HKD |
Net Margin |
26%
|
Country | JP |
Market Cap | 6.8T JPY |
Net Margin |
24%
|
Country | CH |
Market Cap | 37.9B CHF |
Net Margin |
12%
|
Country | DK |
Market Cap | 200.9B DKK |
Net Margin |
19%
|
Country | US |
Market Cap | 16.9B USD |
Net Margin |
11%
|
Country | KR |
Market Cap | 9.9T KRW |
Net Margin |
-358%
|
Country | CA |
Market Cap | 6.9B USD |
Net Margin |
-8%
|
Country | CN |
Market Cap | 48.6B CNY |
Net Margin |
42%
|
Country | US |
Market Cap | 6.3B USD |
Net Margin |
29%
|
Country | US |
Market Cap | 6.1B USD |
Net Margin |
9%
|
Country | UK |
Market Cap | 4.8B GBP |
Net Margin |
7%
|
OrbusNeich Medical Group Holdings Ltd
Glance View
OrbusNeich Medical Group Holdings Ltd. operates as an investment holding company. The company employs 880 full-time employees The company went IPO on 2022-12-23. The firm is engaged in the design, development, manufacture, distribution and sale of interventional medical devices for the treatment of coronary heart disease and peripheral vascular diseases. The firm's main products include percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) balloons. In addition, the Company's products also include semi-compliant balloons and scoring balloons for pre-dilatation and lesion preparation, coronary stents for implantation, non-compliant balloons for post-dilatation and specialty catheters. The firm mainly conducts its businesses in domestic and overseas markets.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on OrbusNeich Medical Group Holdings Ltd's most recent financial statements, the company has Net Margin of 25.6%.